ADMA Biologics Inc (ADMA)

Quick ratio

		Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019
Cash	US$ in thousands	86,707	88,244	45,325	51,352	74,157	62,513	69,204	86,522	34,906	52,415	69,505	51,089	34,411	42,409	61,966	55,921	59,675	75,781	101,236	26,752
Short-term investments	US$ in thousands	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Receivables	US$ in thousands	50,140	30,113	49,600	27,421	31,319	36,732	26,518	15,505	20,902	18,884	25,630	28,577	20,393	23,545	15,362	13,237	6,335	6,514	7,108	3,470
Total current liabilities	US$ in thousands	44,891	44,177	53,088	49,806	41,841	41,952	36,728	39,267	44,440	28,072	31,567	30,378	32,337	18,186	21,206	19,947	16,474	12,880	13,908	14,028
Quick ratio		3.05	2.68	1.79	1.58	2.52	2.37	2.61	2.60	1.26	2.54	3.01	2.62	1.69	3.63	3.65	3.47	4.01	6.39	7.79	2.15

September 30, 2024 calculation

Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($86,707K + $—K + $50,140K) ÷ $44,891K
= 3.05

The quick ratio of ADMA Biologics Inc has fluctuated over the past few years. As of September 30, 2024, the quick ratio was 3.05, indicating that the company had $3.05 in liquid assets available to cover each dollar of its current liabilities.

Comparing this to the historical trend, we observe that the quick ratio has generally been above 1, which suggests that ADMA Biologics Inc has had an adequate level of liquid assets to meet its short-term obligations.

There was a notable decrease in the quick ratio from March 31, 2024, where it was 1.79, to December 31, 2023, where it decreased to 1.58. This may indicate a potential strain on the company's ability to cover its short-term liabilities with its quick assets during that period.

Overall, while the quick ratio has shown variability, the recent value of 3.05 as of September 30, 2024, indicates a strong liquidity position for ADMA Biologics Inc. However, it is important for investors and analysts to continue monitoring the company's liquidity position in order to assess its ability to meet short-term obligations in the future.